After positive results from rival Pfizer’s coronavirus vaccine trials, investors may become less fixated on AstraZeneca’s parallel anti-Covid project.
Iconic One Theme | Powered by Wordpress
After positive results from rival Pfizer’s coronavirus vaccine trials, investors may become less fixated on AstraZeneca’s parallel anti-Covid project.